Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 121867 | 4.425 |
09:34 ET | 28088 | 4.425 |
09:36 ET | 18944 | 4.42 |
09:38 ET | 65359 | 4.42 |
09:39 ET | 12634 | 4.4 |
09:41 ET | 28732 | 4.385 |
09:43 ET | 12521 | 4.395 |
09:45 ET | 50293 | 4.3799 |
09:48 ET | 17465 | 4.365 |
09:50 ET | 11817 | 4.365 |
09:52 ET | 56768 | 4.395 |
09:54 ET | 14429 | 4.39 |
09:56 ET | 30243 | 4.4 |
09:57 ET | 5800 | 4.395 |
09:59 ET | 4562 | 4.4 |
10:01 ET | 13994 | 4.405 |
10:03 ET | 10762 | 4.405 |
10:06 ET | 19630 | 4.395 |
10:08 ET | 34282 | 4.39 |
10:10 ET | 25979 | 4.38 |
10:12 ET | 73621 | 4.37 |
10:14 ET | 253498 | 4.375 |
10:15 ET | 4520 | 4.37 |
10:17 ET | 121899 | 4.375 |
10:19 ET | 31852 | 4.365 |
10:21 ET | 41129 | 4.365 |
10:24 ET | 12126 | 4.35 |
10:26 ET | 46365 | 4.355 |
10:28 ET | 19814 | 4.3502 |
10:30 ET | 27814 | 4.34 |
10:32 ET | 18394 | 4.342 |
10:33 ET | 58477 | 4.32 |
10:35 ET | 19579 | 4.34 |
10:37 ET | 30767 | 4.32 |
10:39 ET | 25264 | 4.32 |
10:42 ET | 37101 | 4.31 |
10:44 ET | 28796 | 4.315 |
10:46 ET | 21038 | 4.305 |
10:48 ET | 49108 | 4.3 |
10:50 ET | 51273 | 4.29 |
10:51 ET | 22211 | 4.3002 |
10:53 ET | 33260 | 4.31 |
10:55 ET | 10235 | 4.33 |
10:57 ET | 43464 | 4.31 |
11:00 ET | 10631 | 4.315 |
11:02 ET | 50291 | 4.32 |
11:04 ET | 28587 | 4.315 |
11:06 ET | 48231 | 4.31 |
11:08 ET | 25843 | 4.32 |
11:09 ET | 19200 | 4.325 |
11:11 ET | 14633 | 4.31 |
11:13 ET | 70015 | 4.31 |
11:15 ET | 65524 | 4.31 |
11:18 ET | 128054 | 4.325 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.5x | --- |
SpringWorks Therapeutics Inc | 2.7B | -7.1x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.2x | --- |
MoonLake Immunotherapeutics | 2.5B | -52.3x | --- |
IDEAYA Biosciences Inc | 2.7B | -17.8x | --- |
Iovance Biotherapeutics Inc | 2.4B | -4.5x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 5,155.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.